drugset / Trial / NCT00725374

A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)

NCT00725374

Phase 3 Completed 102 enrolled Organon and Co
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to compare changes in the expression of the proliferation marker Ki-67 in malignant breast tissue after treatment with tibolone or placebo in postmenopausal women who need to undergo surgery for primary breast cancer

Timeline

Start
2002-12-15
Primary completion
2005-04-15
Completion
2005-04-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tibolone Other / unclassified 2.5 mg

Indications